To include your compound in the COVID-19 Resource Center, submit it here.

Dexanabinol (HU-211): Began Phase III study

Pharmos Corp. (PARS; EASD:PHRM), Iselin, N.J.
Product: Dexanabinol (HU-211)
Business: Neurological
Therapeutic

Read the full 122 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE